Treatment of pure red cell aplasia after major ABO-incompatible bone marrow transplantation resistant to erythropoietin. Bone Marrow Transplantation Team.
A case of pure red cell aplasia after major ABO-incompatible bone marrow transplantation with long duration of up to 482 days is presented. The patient exhibited resistance to treatment using intravenous gamma globulin, prednisolone and 8 week administration of erythropoietin. The patient finally responded to treatment using erythropoietin and methylprednisolone simultaneously. Because of its safety and efficacy, it might be worthwhile to try erythropoietin with methylprednisolone, if necessary, for pure red cell aplasia complicating major ABO-incompatible bone marrow transplantation.
Ohashi
K
K
Department of Hematology, Tokyo Metropolitan Komagome Hospital, Japan.
Akiyama
H
H
Takamoto
S
S
Tanikawa
S
S
Sakamaki
H
H
Onozawa
Y
Y
D000017:ABO Blood-Group System / Q000276:immunology*; D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000276:immunology*; D003131:Combined Modality Therapy; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*; D006648:Histocompatibility / Q000276:immunology*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D008297:Male; D008775:Methylprednisolone / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D012010:Red-Cell Aplasia, Pure / Q000188:drug therapy* / Q000209:etiology* / Q000628:therapy; D013997:Time Factors
D000017:ABO Blood-Group System; D016756:Immunoglobulins, Intravenous; D004921:Erythropoietin; D011239:Prednisolone; D008775:Methylprednisolone